NRD
SLNO

Nebula Research & Development’s Soleno Therapeutics SLNO Stock Holding History

Nebula Research & Development’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,469
Closed -$1.03M – 1133
2025
Q1 		$1.03M Buy
+14,469
New +$705K 0.1% 363
2024
Q4 		– Sell
-4,358
Closed -$220K – 1088
2024
Q3 		$220K Buy
+4,358
New +$209K 0.03% 802

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Nebula Research & Development's SLNO Position: Q2 2025 in Review

Nebula Research & Development sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 14,469 shares — an estimated $1.03M sold.

Nebula Research & Development first reported a position in SLNO in Q3 2024 and held it in 2 quarters. The position peaked at $1.03M in Q1 2025. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • Nebula Research & Development reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 14,469 Soleno Therapeutics shares in Q2 2025, an estimated $1.03M.
  • Nebula Research & Development first reported a position in Soleno Therapeutics in Q3 2024 and held it in 2 quarters.
  • Nebula Research & Development's Soleno Therapeutics position peaked at $1.03M in Q1 2025.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.